and to analyze its efficacy combined with trimethoprim-sulfamethoxazole (TMP/SMX) as treatment for experimental PCM. Our aim in the present work was to characterize a monoclonal antibody (mAbF1.4) raised against a cell wall glycoconjugate fraction of Paracoccidioides spp. Protection mediated by mAbs used to treat experimental paracoccidioidomycosis (PCM) has been demonstrated previously.
Monoclonal antibodies (mAbs) are promising alternatives to treat infectious diseases, especially given their potential for applications in combination therapies with antimicrobial drugs to enhance the antifungal efficacy. 4Laboratory of Medical Mycology, Institute of Tropical Medicine of São Paulo, Department of Dermatology, School of Medicine, University of São Paulo, São Paulo, Brazil.3Department of Medicine (Division of Infectious Diseases), Microbiology and Immunology, Albert Einstein College of Medicine, New York City, NY, United States.2BIDiagnostics, Centro de Inovação, Empreendedorismo e Tecnologia (CIETEC)/Universidade de São Paulo, São Paulo, Brazil.1Instituto de Ciências Biomédicas, Departamento de Microbiologia, Universidade de São Paulo, São Paulo, Brazil.Lopes-Bezerra 1,2, Joshua Daniel Nosanchuk 3 and Carlos Pelleschi Taborda 1,4* Camila Boniche-Alfaro 1*, Brenda Kischkel 1, Luciana Thomaz 1, Monique Maria Carvalho-Gomes 1, Leila M.
0 kommentar(er)
